Who owns MoonLake Immunotherapeutics?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of MLTX from SEC Form 13F filings across 171 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 171 institutions disclosed 73.1M shares of MoonLake Immunotherapeutics worth $1.42B — about 98.9% of shares outstanding; the largest disclosed holder is BVF INC/IL. Source: SEC Form 13F filings, parsed by EvidInvest.
171
13F holders
$1.42B
value, 2026 filers
98.9%
of shares outstanding (73.1M sh)
42
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of MLTX's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BVF INC/IL | 16.0M | $311.5M | 8.0% | 21.6% | 0.0% |
| 2 | Deep Track Capital, LP | 7.0M | $136.3M | 2.0% | 9.5% | +9.2% |
| 3 | T. Rowe Price Investment Management, Inc.NEW | 4.3M | $83.3M | 0.1% | 5.8% | new |
| 4 | D. E. Shaw & Co., Inc. | 3.4M | $65.5M | 0.0% | 4.6% | +40.8% |
| 5 | Cormorant Asset Management, LP | 3.2M | $62.4M | 3.2% | 4.3% | -28.5% |
| 6 | Jupiter Topco LLCNEW | 3.1M | $60.1M | 0.0% | 4.2% | new |
| 7 | Logos Global Management LP | 2.7M | $52.1M | 2.2% | 3.6% | +78.3% |
| 8 | Weiss Asset Management LP | 2.6M | $50.3M | 0.5% | 3.5% | +51.1% |
| 9 | CITADEL ADVISORS LLC | 2.0M | $38.4M | 0.0% | 2.7% | +49.0% |
| 10 | TWO SIGMA INVESTMENTS, LP | 1.7M | $33.4M | 0.0% | 2.3% | +52.8% |
| 11 | MPM BIOIMPACT LLC | 1.6M | $31.3M | 1.9% | 2.2% | -11.3% |
| 12 | Vivo Capital, LLC | 1.4M | $27.3M | 2.5% | 1.9% | +40.0% |
| 13 | JPMORGAN CHASE & CO | 1.4M | $27.6M | 0.0% | 1.9% | +27.4% |
| 14 | Point72 Asset Management, L.P. | 1.2M | $22.6M | 0.0% | 1.6% | -15.3% |
| 15 | BlackRock, Inc. | 1.1M | $21.3M | 0.0% | 1.5% | +7.1% |
| 16 | PRICE T ROWE ASSOCIATES INC /MD/ | 1.0M | $20.3M | 0.0% | 1.4% | -19.6% |
| 17 | Balyasny Asset Management L.P. | 912,715 | $17.8M | 0.0% | 1.2% | -14.3% |
| 18 | GREAT POINT PARTNERS LLC | 855,813 | $16.7M | 3.1% | 1.2% | +71.2% |
| 19 | JANE STREET GROUP, LLC | 853,386 | $16.6M | 0.0% | 1.2% | +88.1% |
| 20 | Candriam S.C.A. | 769,766 | $15.0M | 0.1% | 1% | -5.9% |
| 21 | BANK OF AMERICA CORP /DE/ | 751,897 | $14.6M | 0.0% | 1% | +3.7% |
| 22 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 750,777 | $14.6M | 0.0% | 1% | +970.4% |
| 23 | Trails Edge Capital Partners, LPNEW | 750,000 | $14.6M | 2.3% | 1% | new |
| 24 | HRT FINANCIAL LP | 679,244 | $13.2M | 0.0% | 0.9% | +39.3% |
| 25 | RENAISSANCE TECHNOLOGIES LLC | 643,268 | $12.5M | 0.0% | 0.9% | +132.4% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.